NCT05507541 2026-04-22
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting
Clinical Trials
31 trialsNCT06859008 2026-04-20
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT07539688 2026-04-20
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07528352 2026-04-17
REBEL
University of Utah
Phase 1 Not yet recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT06768905 2026-04-16
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT04491370 2026-04-15
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
Phase 1/2 Recruiting
NCT04978584 2026-04-15
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07476105 2026-04-15
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
Fondazione Italiana Linfomi - ETS
Phase NA Not yet recruiting
NCT07523737 2026-04-15
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Recruiting
NCT01241734 2026-04-08
RICER
Hackensack Meridian Health
Phase 1/2 Completed
NCT04488354 2026-04-08
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Phase 1 Completed
NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05852717 2026-04-08
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07517705 2026-04-08
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase NA Not yet recruiting
NCT01679119 2026-04-07
INCA
University College, London
Phase 2 Completed
NCT06208735 2026-04-03
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT05257018 2026-04-02
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Fudan University
Phase 2 Recruiting
NCT05618366 2026-04-02
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT07507318 2026-04-02
DEL-MRD-CHID
Fudan University
Phase 2 Not yet recruiting
NCT07451652 2026-04-01
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Recruiting
NCT02051257 2026-03-31
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05757219 2026-03-31
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06687772 2026-03-31
CNS-PHLAT
Washington University School of Medicine
Phase 2 Recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07499271 2026-03-30
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07494565 2026-03-27
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting
NCT07493148 2026-03-25
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
The First Hospital of Jilin University
Phase 2 Recruiting
NCT07493486 2026-03-25
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Zhejiang Cancer Hospital
Phase 2 Completed